Table 2: Demographic
Data.
|
Age in years mean,
(range) |
78, (58-92) |
|
Sex (% male) |
42% |
|
Lesion type number, (%) |
|
|
Occult |
28, (56%) |
|
Classic |
14, (28%) |
|
PCV |
7, (14%) |
|
RAP |
1, (2%) |
|
BCVA mean, (range) |
71, (51 -85) |
|
Time from onset
of treatment with bevacizumab to switching to aflibercept (mean, range), n = 27 |
32 (9-60) |
|
Time from
onset of treatment with ranibizumab to switching to
aflibercept (mean, range), n = 23 |
7 (5-24) |
|
Duration of disease in
months mean, (range) |
35, (9-60) |
|
Number of previous
anti-VEGF treatments median, (range) |
|
|
Bevacizumab |
17, (6-35) |
|
Ranibizumab |
0, (3-29) |
|
Bevacizumab
and Ranibizumab |
22 (9-44) |
|
Modality of treatment
number, (%) |
|
|
Bevacizumab monotherapy |
27 (54%) |
|
Ranibizumab monotherapy |
2 (4%) |
|
Bevacizumab
and ranibizumab |
21 (42%) |